+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Clinical Juvenile Arthritis Disease Activity Score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis



Clinical Juvenile Arthritis Disease Activity Score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis



Annals of the Rheumatic Diseases 77(3): 336-342



To assess if the Juvenile Arthritis Disease Activity Score (JADAS71) could be used to correctly identify patients with juvenile idiopathic arthritis (JIA) in need of antitumour necrosis factor therapy (anti-TNF) therapy 3 and 6 months after start of methotrexate (MTX). Monocentric retrospective cohort study from 2011 to 2015 analysing all patients with oligoarticular JIA (OJIA) (n=39) and polyarticular course JIA (PJIA) (n=74) first starting MTX. Three and 6 months after MTX start, clinical and laboratory features and the 2011 American College of Rheumatology (ACR) JIA treatment recommendations (ACR clinical practice guideline (ACR-CPG)) were compared between groups starting and not starting anti-TNF therapy. The sensitivity and specificity of the ACR-CPG, JADAS71 and the clinical JADAS to identify non-responders after 12 months were calculated. Physicians escalated patients with significantly higher physician global assessment, clinical JADAS (cJADAS) and patient Visual Analogue Scale (VAS). The decision not to escalate was correct in 70%-75% as shown by MTX response. The implementation of the ACR-CPG would increase the current anti-TNF use from 12% to 65%. The use of (c)JADAS in identifying patients in need of anti-TNF therapy outperformed the ACR-CPG with a much higher sensitivity, specificity and accuracy. The cJADAS threshold for treatment escalation at month 3 and 6 was >5 and >3 for OJIA and >7 and >4 for PJIA, respectively. The performance of the cJADAS decreased when the patient VAS contribution to the total score was restricted and overall did not improve by adding the erythrocyte sedimentation rate. The cJADAS identifies patients in need of anti-TNF and is a user-friendly tool ready to be used for treat to target in JIA. The patient VAS is a critical item in the cJADAS for the decision to escalate to anti-TNF.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 059508714

Download citation: RISBibTeXText

PMID: 29138257

DOI: 10.1136/annrheumdis-2017-212104


Related references

Finding specific 10-joint Juvenile Arthritis Disease Activity Score (JADAS10) and clinical JADAS10 cut-off values for disease activity levels in non-systemic juvenile idiopathic arthritis: a Finnish multicentre study. Rheumatology 55(4): 615-623, 2016

Fri0345Response to etanercept in juvenile idiopathic arthritis using the continuous measure juvenile arthritis disease activity score Jadas:. Annals of the Rheumatic Diseases 71(Suppl 3): 431.1-431, 2013

Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis. Annals of the Rheumatic Diseases 72(12): 1983-1988, 2014

Thu0310Performance of the juvenile arthritis disease activity score Jadas compared to the acr pediatric measures of response in 1470 juvenile idiopathic arthritis patients. Annals of the Rheumatic Diseases 71(Suppl 3): 260.3-261, 2013

Definition of improvement in juvenile idiopathic arthritis using the juvenile arthritis disease activity score. Rheumatology 53(7): 1229-1234, 2014

Interpretation of the Juvenile Arthritis Disease Activity Score: responsiveness, clinically important differences and levels of disease activity in prospective cohorts of patients with juvenile idiopathic arthritis. Rheumatology 53(2): 307-312, 2014

Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the juvenile arthritis disease activity score. Arthritis and Rheumatism 64(7): 2366-2374, 2012

Defining criteria for disease activity states in nonsystemic juvenile idiopathic arthritis based on a three-variable juvenile arthritis disease activity score. Arthritis Care and Research 66(11): 1703-1709, 2014

FRI0330Development of cut-off values for high disease activity in juvenile idiopathic arthritis based on the juvenile arthritis disease activity score (JADAS):. Annals of the Rheumatic Diseases 71(Suppl 3): 425.3-426, 2013

Juvenile arthritis disease activity score is a better reflector of active disease than the disease activity score 28 in adults with polyarticular juvenile idiopathic arthritis. Annals of the Rheumatic Diseases 75(3): 635-636, 2016

Defining criteria for high disease activity in juvenile idiopathic arthritis based on the juvenile arthritis disease activity score. Annals of the Rheumatic Diseases 73(7): 1380-1383, 2014

THU0237Disease Activity in Patients with Juvenile Spondyloarthropathy on anti-TNF Therapy as Measured by The Juvenile Arthritis Disease Activity Score (JADAS)-10 and The Juvenile Spondyloarthritis Disease Activity Index (JSPADA). Annals of the Rheumatic Diseases 75(Suppl 2): 273.3-274, 2016

Comparison of the Disease Activity Score-28 and Juvenile Arthritis Disease Activity Score in the juvenile idiopathic arthritis. Revista Brasileira de Reumatologia 55(1): 31-36, 2017

Treat to target (drug-free) inactive disease in DMARD-naive juvenile idiopathic arthritis: 24-month clinical outcomes of a three-armed randomised trial. Annals of the Rheumatic Diseases 2018, 2018

Abbott proposes in Europe and the U.S.A. the approval of Humira (adalimumab) for therapy of juvenile idiopathic arthritis. Pediatric clinical trial shows very promising results in juvenile rheumatoid arthritis. Kinderkrankenschwester 26(8): 335-336, 2007